AU3398793A - Anti-tumor method and anti-tumor agent - Google Patents

Anti-tumor method and anti-tumor agent

Info

Publication number
AU3398793A
AU3398793A AU33987/93A AU3398793A AU3398793A AU 3398793 A AU3398793 A AU 3398793A AU 33987/93 A AU33987/93 A AU 33987/93A AU 3398793 A AU3398793 A AU 3398793A AU 3398793 A AU3398793 A AU 3398793A
Authority
AU
Australia
Prior art keywords
tumor
agent
tumor agent
tumor method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33987/93A
Other languages
English (en)
Inventor
Not Given Name
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIO DEFENCE INSTITUTE CO Ltd
Original Assignee
BIO DEFENCE INSTITUTE CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIO DEFENCE INSTITUTE CO Ltd filed Critical BIO DEFENCE INSTITUTE CO Ltd
Publication of AU3398793A publication Critical patent/AU3398793A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU33987/93A 1992-03-05 1993-03-04 Anti-tumor method and anti-tumor agent Abandoned AU3398793A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4048840A JPH05246889A (ja) 1992-03-05 1992-03-05 制癌方法および制癌剤
JP4-48840 1992-03-05

Publications (1)

Publication Number Publication Date
AU3398793A true AU3398793A (en) 1993-09-09

Family

ID=12814449

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33987/93A Abandoned AU3398793A (en) 1992-03-05 1993-03-04 Anti-tumor method and anti-tumor agent

Country Status (15)

Country Link
EP (1) EP0563627A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH05246889A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR930019225A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1079400A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU3398793A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9300764A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2090957A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ34293A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI930976L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT67859A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL104944A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO930798L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ247057A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK15993A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA931558B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
IT1274592B (it) * 1994-08-05 1997-07-18 Angela Turiano Composizione farmaceutica per la terapia tumorale contenente xenoantigeni
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
CA2275141A1 (en) * 1996-10-29 1998-05-07 Thomas Spies Cell stress regulated human mhc class i gene
FR2775189B1 (fr) * 1998-07-24 2001-06-08 Commissariat Energie Atomique Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g
JP4470007B2 (ja) * 1998-02-20 2010-06-02 コミサリア・ア・レネルジー・アトミーク Ｈｌａ−ｇを発現する、抗癌治療に感受性な腫瘍を選択する方法およびその使用
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
EP1245675A1 (en) * 2001-03-28 2002-10-02 Kohji Egawa Cancer cell-specific HLA-F antigen and a diagnostic method of cancer by using thereof
CA2518237A1 (en) * 2003-03-04 2004-09-16 Greenville Hospital System Antitumor agents comprising a targeting portion and an immune response triggering portion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung

Also Published As

Publication number Publication date
JPH05246889A (ja) 1993-09-24
KR930019225A (ko) 1993-10-18
EP0563627A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-04-27
HU9300612D0 (en) 1993-05-28
CZ34293A3 (en) 1994-01-19
EP0563627A2 (en) 1993-10-06
NZ247057A (en) 1995-10-26
FI930976A7 (fi) 1993-09-06
ZA931558B (en) 1993-09-27
CA2090957A1 (en) 1993-09-06
CN1079400A (zh) 1993-12-15
FI930976A0 (fi) 1993-03-04
SK15993A3 (en) 1993-10-06
BR9300764A (pt) 1993-09-28
NO930798D0 (no) 1993-03-04
FI930976L (fi) 1993-09-06
NO930798L (no) 1993-09-06
HUT67859A (en) 1995-03-23
IL104944A0 (en) 1993-07-08

Similar Documents

Publication Publication Date Title
AU5237093A (en) Attachment apparatus and method
AU4409893A (en) Back strengthening device and method
AU4539493A (en) Object location process and apparatus
AU2029592A (en) Fastening system and method
AU4013193A (en) Method of maintaining relationships between elements
AU3208793A (en) Abrasive article and method
AU675671B2 (en) System and method for knowledge based design
AU6400294A (en) Tripterinin compound and method
AU7181891A (en) Improved still and method
AU4233593A (en) Moving harness and method of use
AU1102795A (en) Location apparatus and method
AU3401293A (en) Radar apparatus and method
AU7733694A (en) Improved photokeratoscope apparatus and method
AU4489693A (en) Apparatus and methods for improved construction
AU5675494A (en) Cooling method and apparatus
AU5937194A (en) Gas-lance apparatus and method
AU7969994A (en) Keratorefractive system and method
AU3385693A (en) Determination method
AU3398793A (en) Anti-tumor method and anti-tumor agent
AU3593793A (en) Putting and chipping apparatus
AU6015096A (en) Antiviral method and antiviral agent
AU3464693A (en) Communication method and apparatus
AU638098B2 (en) Mining apparatus and methods
AU4152793A (en) Continuous melt-coating method and apparatus
GB9224295D0 (en) Method and composition